CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK
59.99
24-January-25 16:45:00
15 minutes delayed
Stocks
-2.30
-3.69%
Today's range
59.35 - 62.29
ISIN
N/A
Source
NASDAQ
-
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
08 Jan 2024 08:00:01 By Nasdaq GlobeNewswire
-
Court Finds Corcept Therapeutics’ Patents Not Infringed
02 Jan 2024 08:00:00 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
01 Nov 2023 16:05:00 By Nasdaq GlobeNewswire
-
Corcept Appoints Monica Tellado as President, Emerging Markets
01 Nov 2023 08:00:00 By Nasdaq GlobeNewswire
-
Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
26 Oct 2023 16:05:00 By Nasdaq GlobeNewswire
-
25 Oct 2023 16:05:00 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
02 Aug 2023 16:05:01 By Nasdaq GlobeNewswire
-
26 Jul 2023 16:05:00 By Nasdaq GlobeNewswire
-
Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
17 Jul 2023 16:05:00 By Nasdaq GlobeNewswire
-
27 Jun 2023 08:00:00 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
03 May 2023 16:05:01 By Nasdaq GlobeNewswire
-
26 Apr 2023 16:05:01 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces Final Results of Tender Offer
05 Apr 2023 16:05:00 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Announces Preliminary Results of Tender Offer
03 Apr 2023 08:00:01 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Initiates CATALYST Clinical Trial
28 Mar 2023 16:05:00 By Nasdaq GlobeNewswire
-
06 Mar 2023 08:00:00 By Nasdaq GlobeNewswire
-
28 Feb 2023 16:05:01 By Nasdaq GlobeNewswire
-
14 Feb 2023 16:05:00 By Nasdaq GlobeNewswire
-
13 Feb 2023 08:00:00 By Nasdaq GlobeNewswire
-
Corcept Therapeutics Provides Miricorilant Clinical Development Update
08 Dec 2022 08:00:02 By Nasdaq GlobeNewswire